IL129623A0 - Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes - Google Patents

Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Info

Publication number
IL129623A0
IL129623A0 IL12962397A IL12962397A IL129623A0 IL 129623 A0 IL129623 A0 IL 129623A0 IL 12962397 A IL12962397 A IL 12962397A IL 12962397 A IL12962397 A IL 12962397A IL 129623 A0 IL129623 A0 IL 129623A0
Authority
IL
Israel
Prior art keywords
syndromes
prevention
treatment
related diseases
derivatives useful
Prior art date
Application number
IL12962397A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL129623A0 publication Critical patent/IL129623A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL12962397A 1996-10-28 1997-10-28 Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes IL129623A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK120196 1996-10-28
PCT/DK1997/000481 WO1998018774A1 (en) 1996-10-28 1997-10-28 Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Publications (1)

Publication Number Publication Date
IL129623A0 true IL129623A0 (en) 2000-02-29

Family

ID=8102120

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12962397A IL129623A0 (en) 1996-10-28 1997-10-28 Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Country Status (8)

Country Link
EP (1) EP0937059A1 (de)
JP (1) JP2001502706A (de)
AU (1) AU744403B2 (de)
CA (1) CA2269936A1 (de)
IL (1) IL129623A0 (de)
NO (1) NO992009L (de)
WO (1) WO1998018774A1 (de)
ZA (1) ZA979643B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153768A (en) * 1996-12-13 2000-11-28 C & C Research Laboratories Benzopyran derivatives
DK1140889T3 (da) * 1998-12-30 2003-12-22 Signal Pharm Inc Forbindelser og metoder til modulation af estrogen-receptorer
PT1355906E (pt) * 2001-01-24 2005-05-31 Chiesi Farma Spa Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CA2581316C (en) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
EP2635273B1 (de) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoidzusammensetzungen und verfahren zur krebsbehandlung
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
WO1998018774A1 (en) 1998-05-07
JP2001502706A (ja) 2001-02-27
CA2269936A1 (en) 1998-05-07
NO992009L (no) 1999-06-25
AU4771897A (en) 1998-05-22
ZA979643B (en) 1998-04-28
NO992009D0 (no) 1999-04-27
EP0937059A1 (de) 1999-08-25
AU744403B2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU4966497A (en) Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
HUP9900790A3 (en) Imidazoquinazoline derivatives
ZA9710322B (en) Process for the preparation of benzyl-ethers.
AU8181798A (en) Adjustable leg
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL129623A0 (en) Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129622A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129618A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU663832B2 (en) Easy chess-like game
IL129624A0 (en) Novel (+)-enantiomers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129626A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA972708B (en) Pharmaceutical compositions and methods for the manufacture thereof.
GB9608657D0 (en) Novel treatment
IL129617A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
GB2322785B (en) Pasteurizing process
GB2302691B (en) Oxaindene derivatives and process for the preparation thereof
AU7639998A (en) Pyrrolo{2,1,5-cd}indolizine derivatives useful in the prevention or treatment ofestrogen related diseases or syndromes
ZA9610708B (en) Oxaindene derivatives and process for the preparation thereof.
ZA984823B (en) Pyrrolo(2,1,5-cd)indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA984822B (en) Pyrrolo (2,11,5-cd) indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA975061B (en) Manufacture of articles.
HK1004660B (en) Composition for treating hyperosteogeny and process for the preparation thereof
IL108277A0 (en) 3-Metyl-7-n-propylxantihine derivatives and processes for the preparation thereof
AU7539596A (en) Oxaindene derivatives and process for the preparation thereof